Would mean more if it proved B useful for respiratory problems; Asthma and COPD alone has a revenue stream of $50B+/yr. Many additional respiratory conditions it could work on as well.
It is my understanding the accelerated emergency testing would be free and IPIX would retain all rights to the drug and any revenues accrued. IPIX would also benefit from drug approval for whatever indications are approved viral, antibiotic or antiinflammatory and for any means of delivery, IV or inhaled.
Market Data 
Markets 
AI
